Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
24.90M | 23.41M | 19.64M | 18.08M | 14.16M | Gross Profit |
10.16M | 8.39M | -521.00K | -1.54M | 3.68M | EBIT |
-413.00K | -1.46M | -3.44M | -4.12M | -4.38M | EBITDA |
-1.01M | -1.23M | -1.70M | -2.93M | -2.75M | Net Income Common Stockholders |
-2.77M | -3.13M | -3.49M | -4.47M | -3.54M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
3.72M | 2.47M | 5.39M | 8.69M | 4.64M | Total Assets |
20.58M | 18.70M | 20.56M | 22.05M | 11.22M | Total Debt |
1.37M | 1.65M | 1.40M | 1.64M | 562.44K | Net Debt |
-2.27M | -755.00K | -3.74M | -7.05M | -4.08M | Total Liabilities |
7.66M | 7.13M | 6.25M | 7.67M | 4.51M | Stockholders Equity |
12.92M | 11.57M | 14.31M | 14.35M | 6.71M |
Cash Flow | Free Cash Flow | |||
― | -2.23M | -3.65M | -3.73M | -2.00M | Operating Cash Flow |
115.00K | -1.45M | -1.88M | -2.31M | -1.16M | Investing Cash Flow |
-1.22M | -728.00K | -3.97M | -4.31M | -1.35M | Financing Cash Flow |
2.28M | -485.00K | 2.32M | 10.54M | -544.06K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | AU$609.97M | 16.51 | 12.07% | 6.52% | 1.63% | -18.01% | |
66 Neutral | $4.51B | 12.22 | 5.40% | 3.63% | 4.14% | -12.01% | |
66 Neutral | AU$117.48M | 28.87 | 1.60% | 4.35% | -10.06% | ― | |
54 Neutral | AU$29.30M | ― | -22.62% | ― | 6.37% | 20.31% | |
$19.28M | ― | -80.26% | ― | ― | ― | ||
44 Neutral | AU$48.14M | ― | -10.18% | ― | -6.95% | 40.87% |
De.mem Limited has announced changes in its board composition, appointing Mr. Andreas Hendrik De Wit as the new Non-Executive Chairman. Mr. De Wit, who has extensive international board and leadership experience, previously served as CEO of Asia Pacific for Fresenius Medical Care. His strategic and capital markets experience, along with his significant shareholding in De.mem, positions him to lead the company’s next phase of global expansion. The board also appointed Michael Edwards as the lead independent director, who has been instrumental in De.mem’s ASX listing and expansion efforts.
De.mem Ltd. has released its consolidated financial report for the year ending December 31, 2024. The report outlines the company’s financial performance and strategic positioning, indicating a continued focus on expanding its market presence and enhancing its operational capabilities. The release is significant for stakeholders as it highlights De.mem’s commitment to growth and its strategic initiatives to strengthen its industry position.
De.mem Limited has announced that its Annual General Meeting (AGM) will be held virtually on May 20, 2025, at 4:00 PM AEST. Shareholders are encouraged to access the meeting materials online and lodge their proxy votes in advance. This shift to a virtual format reflects the company’s adaptation to digital communication trends, potentially increasing shareholder participation and engagement.
De.mem Limited reported record cash receipts of approximately $7.9 million for the March Quarter 2025, marking the highest quarterly cash receipts in the company’s history. This achievement reflects a 20% growth compared to the prior corresponding period and demonstrates the company’s strong and stable growth momentum, with 24 consecutive quarters of cash receipts growth. The company also reported positive quarterly operating cash flows for the third consecutive quarter, driven by strong performances from its Australian and German entities. De.mem’s strategic positioning and successful market penetration, including the launch of domestic water treatment products in China, Indonesia, and Japan, have contributed to its robust financial performance.
De.mem Ltd. has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The company will be quoting 110,000 ordinary fully paid securities, which were issued on April 1, 2025. This move could potentially enhance the company’s financial flexibility and market presence, offering stakeholders an opportunity to engage with the company’s growth prospects.
De.mem Ltd. announced the cessation of 250,000 performance rights due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could have implications for stakeholders regarding the company’s operational and financial strategies moving forward.
De.mem Limited has announced that its Annual General Meeting (AGM) will be held on May 20, 2025. The company has set April 3, 2025, as the closing date for director nominations. This announcement is part of De.mem’s compliance with ASX Listing Rules and reflects its ongoing corporate governance practices. The AGM and director nominations are significant for stakeholders as they provide opportunities for strategic input and leadership decisions that may influence the company’s future direction.
De.mem Ltd has reported record financial results for the calendar year 2024, with cash receipts reaching approximately $28.4 million, marking a 15% increase from the previous year. The company achieved a positive operating cash flow for the first time, indicating strong financial health and growth momentum, supported by a robust balance sheet and a promising outlook for 2025.
De.mem Ltd. has released its updated corporate governance statement for the financial year ending December 31, 2024, which adheres to the ASX Corporate Governance Council’s principles and recommendations. The statement, approved by the board and available on the company’s website, outlines the company’s compliance with governance practices, including board responsibilities, director appointments, and accountability measures, enhancing transparency and stakeholder confidence.
De.mem Limited reported a 6.4% increase in revenues to $24.9 million for the year ending December 2024, alongside a reduction in net loss by 11.6% to $2.77 million. The company’s gross margins improved significantly from 35% to 41%, and it ended the year with a stronger cash position of $3.63 million, supporting its growth plans. Despite the net loss, the company showed improved financial metrics, indicating a positive trajectory in its operations and market positioning.
De.mem Ltd announced a strategic distribution agreement with Firmbase Pte Ltd to expand its presence in Asian markets, specifically targeting China, Indonesia, and Japan. This partnership marks a significant step for De.mem as they have received their first commercial order worth $15,000 from Firmbase Singapore for their compact Ultrafiltration systems, marking successful entry into the substantial Chinese home water filtration market. De.mem’s standardized Ultrafiltration membrane systems, featuring NSF-certified components, cater to both residential and industrial applications, enhancing their market positioning in the growing water filtration industry.